Remove Generic Drugs Remove Marketing Remove Medicine Remove Pharma Companies
article thumbnail

Sweeping changes in leaked EU pharma law draft reignite profit vs access conflict

Pharmaceutical Technology

The overhaul will address drug marketing exclusivity length, pricing, patient access, innovation incentives, antimicrobial resistance, clinical trials, supply chain security and shortages, and environmental impact. She also cautioned against believing that all of the problems with Europe’s medicines can be solved with regulation.

article thumbnail

PBMs and insurers want your prescription money

World of DTC Marketing

anti-kickback law that the drugmaker said prevented it from helping heart failure patients, many with low incomes, afford the medicine that costs $225,000 annually. Pharma companies have very little control over patients’ prices for their Rxs. A federal appeals court rejected Pfizer’s challenge to a U.S.

Pharmacy 226
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Disruption in healthcare is coming

World of DTC Marketing

PBMs, insurers, pharma companies, and hospitals don’t want to give up their profits even if it’s better for the general population. Then there is the cost of generic drugs. bil­lion in 2020 if it had pur­chased 77 of 89 drugs from Cuban’s firm.

Pharmacy 227
article thumbnail

Common sense approach to the pharma industry

World of DTC Marketing

Pharma companies are still too focused on profits while people continue to rely on prescription drugs to compensate for unhealthy lifestyles. The headline and byline in a Times editorial said it all “Don’t Fall for Big Pharma’s Savior Act, Heroic work went into the development of the coronavirus vaccines.

article thumbnail

In the News: October Regulatory and Development Updates

Camargo

When the FDA requires a product’s labeling to include a boxed warning (also called a “black box warning” because the text is surrounded by black border), the potential market value of the drug often drops severely. In 2019, Foundation Medicine and Bayer Healthcare Pharmaceuticals, Inc.

article thumbnail

Pioneering access to complex generic products 

Drug Discovery World

Claire D’Abreau-Hayling, Chief Scientific Officer at Sandoz, examines how generic products can relieve industry pressure and improve access to essential medicines. Off-patent medicines today account for about 80% of global prescriptions at an estimated 20% of the total cost.

article thumbnail

Pharma’s climate change vulnerability and opportunity

pharmaphorum

Pharma companies are “highly vulnerable” to the effects of climate change, due to their reliance on global networks. In 2017, the global medicines supply was interrupted when Hurricane Maria hit Puerto Rico, home to more than 500 medical product facilities and producer of 10% of all drugs consumed in America.